Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study
Authors
- Timothy R. Smith (ORCID: https://orcid.org/0000-0001-9607-8985)
- Alexandra Palmer (ORCID: https://orcid.org/0000-0002-4786-4960)
- Sarah Dubrava
- Witold Żmuda
- Margot Johnson
- Robert Frederich (ORCID: https://orcid.org/0000-0002-5175-3112)
- Szilárd Vasas
- Amina Z. Haggag
- Neeta B. Amin (ORCID: https://orcid.org/0000-0002-0727-4683)
- Nikolaos Tsamandouras
- Gina Buckley
- Tilman Schuster
- Qi Zhu (ORCID: https://orcid.org/0000-0002-2529-1225)
Institutions
- Pfizer (United States) (US)
- Anaheim Clinical Trials (US)
- NeuroMetrix (United States) (US)
- Pfizer (China) (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1111/dom.16005
- Citations
- 17
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.08
Funders
- Pfizer